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BACKGROUND: Whether sex disparities exist in overall
burden of disease among human immunodeficiency
virus (HIV)-infected individuals in the Veterans Affairs
healthcare system (VA) is unknown.
OBJECTIVE: To determine whether sex differences exist in
overall burden of disease after 1 year of combined antire-
troviral therapy (ART) amongHIV-infected individuals in VA.
DESIGN: Retrospective cohort study.
PARTICIPANTS: Among patients in the Veterans Aging
Cohort Study Virtual Cohort (VACS-VC), all ART-naïve
HIV-infected Veterans who received VA-based HIV care
between 1996 and 2009.
MAIN MEASURES: Overall burden of disease was
measured using the VACS Index, an index that incor-
porates HIV (e.g. CD4 cell count) and non-HIV bio-
markers (e.g. hemoglobin) and is highly predictive of all-
cause mortality. Possible scores range from 0 to 164,
although scores typically range from 0 to 50 for 80 % of
patients in VACS-VC. A higher score indicates greater
burden of disease (each additional five points indicates
approximately 20 % increased 5-year mortality risk).
ART adherence was measured using pharmacy data.
KEY RESULTS: Complete data were available for 227
women and 8,073 men. At ART initiation, compared with
men, women were younger and more likely to be Black,
less likely to have liver dysfunction, but more likely to
have lower hemoglobin levels. Median VACS Index scores
changed from ART initiation to 1 year after ART initiation:
women’s scores went from 41 to 28 for women (13 point
improvement) and men’s from 42 to 27 for men (15 point
improvement). In multivariable regression, women had
3.6 point worse scores than men after 1 year on ART (p=
0.002); this difference decreased to 3.2 points after
adjusting for adherence (p=0.004).
CONCLUSIONS: In VA, compared to men, women experi-
enced less improvement in overall burden of disease after
1year ofHIV treatment.Further study isneeded to elucidate
the modifiable factors that may explain this disparity.
KEY WORDS: women; Veterans; HIV; health care disparities; burden of
illness.
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S ince the introduction of combined antiretroviral treatment(ART), there has been accumulating evidence of sex
disparities in HIV-related care and outcomes in the United
States, with women, in general, faring worse than men.1–
8 Prior studies have found that HIV-infected women report
worse health-related quality of life8 and have greater HIV-
related morbidity,5 as well as HIV-related6 and all-cause
mortality,6,7 compared to HIV-infected men. These health
disparities have been attributed, in part, to differences in access
to care,1,7 quality of care,1–4 and ART adherence.9–12
It is unknown whether similar disparities exist between HIV-
infected women and men in the Veterans Affairs (VA) health-
care system. VA is the largest single provider of HIV care in the
United States, providing care to over 24,000 HIV-infected
Veterans annually.13 Within VA, women and men share similar
sociodemographic characteristics, such as limited economic
resources. Additionally, the potential barrier of access based on
health insurance is similarly reduced for both groups.
As the number of women Veterans seeking VA care
continues to increase, it is expected that the number of HIV-
infected women in VA care—currently 3 % of HIV-infected
persons in VA care—will also rise.14,15 However, there is a lack
of research examining health outcomes among this unique
population of women Veterans and whether sex disparities in
outcomes exist among HIV-infected persons in VA care.
Therefore, among HIV-infected individuals in VA care, we
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sought to determine whether differences exist by sex in overall
burden of disease after 1 year of ART.
METHODS
Data Source
We used data from the Veterans Aging Cohort Study Virtual
Cohort (VACS-VC), a clinical cohort of 32,747 HIV-infected
persons in care at VA facilities nationally.16 VACS-VC consists
of data from the Clinical Case Registry, the VA’s HIV registry;
the Pharmacy Benefits Management database, which provides
outpatient pharmacy data; and the Decision Support System, a
national database of clinical data including coded diagnoses
and laboratory values. We received Institutional Review Board
approval for this study from VA Connecticut Healthcare
System and the Yale University School of Medicine.
Study Population
Among the HIV-infected persons in the VACS-VC (821
women, 31,926 men), we included persons 1) with a date of
entry to HIV care between January 1, 1996 and December 31,
2009; 2) who were confirmed to be receiving HIV care at a VA
healthcare facility; and 3) who were ART-naïve, defined as
having received no prior ART prescriptions while in VA care
and an HIV RNA level > 500 copies/mL within 6 months prior
to ART initiation. Date of entry to HIV care was defined as the
earliest date of any of the following: ICD-9 code for HIV
diagnosis (042 or V08) (1st inpatient or 2nd outpatient), CD4
cell count, or HIV RNA level. Patients were confirmed to be
receiving HIV care if there was evidence of a CD4 cell count,
HIVRNA level, or ART prescription at a VA healthcare facility.
Measures
Overall burden of disease was measured using the VACS
Index, a validated index predictive of morbidity and
mortality which incorporates HIV and non-HIV bio-
markers.17,18 The VACS Index is calculated using the patient’s
age, CD4 cell count; HIV RNA level and hemoglobin levels;
renal and hepatic function; and Hepatitis C virus serostatus
(Table 1).17,18 Possible VACS Index scores range from 0 to
164 points with higher scores indicating greater burden of
disease and higher risk of morbidity and mortality; scores
range from 0 to 50 points for 80 % of patients in VACS-VC.19
A 5-point difference in VACS Index corresponds to an
approximately 20 % change in 5-year mortality risk.19,20 Time
intervals used to identify routine clinical tests for calculation of
the VACS Index were consistent with prior VACS studies.19
ART adherence was measured using the medication
possession ratio (MPR), a validated measure of medication
adherence. MPR is the sum of the days’ supply of ART in a
specific period divided by the total number of days during
the specified period; in this case, 365 days.21,22 The MPR
was dichotomized as < 80 % (poor adherence) vs. ≥ 80 %
(high adherence).23
Statistical Analysis
We used chi-square and Wilcoxon-rank sum tests to
compare VACS Index components and total VACS Index
scores by sex at ART initiation and after 1 year on ART.
We assessed the association between sex and our
outcome of interest, VACS Index score after 1 year on
ART, with and without adjustment for VACS Index score
at ART initiation, age, and poor ART adherence using
linear regression. VACS Index score at ART initiation
was centered at the median (42), so that the intercept for
models adjusted for score at ART initiation represents
those with the median value rather than zero. Age,
modeled in 5-year increments, was centered at 47, such
that the intercept, in models adjusted for age, represents
the 1-year score for a 47-year-old patient. We used age at
ART initiation when calculating all VACS Index scores to
avoid increasing scores due to the increase in age by
1 year. We included age in multivariate models, because
women in our cohort were younger and we wanted to
adjust for this potential confounder. Associations with
VACS Index score at 1 year after ART initiation are
presented as betas (β) with associated 95 % confidence
intervals (CI) and p values. Statistical analyses were
performed using SAS 9.2 (SAS Institute, Inc., Cary,
North Carolina).
Table 1. Points Used to Generate Veterans Aging Cohort Study
(VACS) Index Score for Overall Burden of Disease
Component VACS Index
Age years < 50 0
50 to 64 12
≥ 65 27
CD4 cells/mm3 ≥ 500 0
350 to 499 6
200 to 349 6
100 to 199 10
50 to 99 28
< 50 29
HIV RNA copies/mL < 500 0
500 to 1×105 7
> 1×105 14
Hemoglobin g/dL ≥ 14 0
12 to 13.9 10
10 to 11.9 22
< 10 38
FIB-4 < 1.45 0
1.45 to 3.25 6
> 3.25 25
eGFR mL/min ≥ 60 0
45 to 59.9 6
30 to 44.9 8
< 30 26
Hepatitis C 5
FIB-4: Fibrosis Index=(years of age×aspartate transaminase)/(platelets in
109/L×square root of alanine transaminase)
eGFR: estimated Glomerular Filtration Rate=186.3×(serum creati-
nine−1.154)×(age−0.203)×(0.742 for women)×(1.21 if black)
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RESULTS
Of 275 women and 9,809 men who met study criteria,
complete data were available for 227 women (82.5 %) and
8,073 men (82.3 %) at both ART initiation and 1 year after.
At ART initiation, women were younger (42 [IQR 37–48]
vs. 47 [IQR 40–53] years, p<0.001) and more likely to be
Black (69.2 % vs. 55.1 %, p<0.001) (Table 2). Women
were less likely to have liver dysfunction (33 % vs. 48 %,
p<0.001), but more likely to have lower hemoglobin levels
(12.0 vs. 13.4 [IQR 12.0–14.6] g/dL, p<0.001). There were
no statistically significant differences by sex with respect to
CD4 cell count (237 [IQR 100–363] vs. 230 [IQR 68–341]
cells/mm3, p=0.07), HIV RNA levels, renal function,
Hepatitis C infection, or VACS Index score.
Association Between Patient Sex and Overall
Burden of Disease 1 Year After ART Initiation
VACS Index scores, our measure of overall burden of
disease, changed for both groups over 1 year of ART
(Fig. 1). Baseline to 1 year scores changed from: 41 to 28
for women (13 point improvement), equivalent to a
decrease of 8.8 % in 5-year mortality risk; and 42 to 27
for men (15 point improvement), a decrease of 10.2 % in 5-
year mortality risk. Because the translation of a difference
in VACS Index score to an expected mortality rate depends
upon baseline score, one must interpret these changes in this
context.
In unadjusted analysis, patient sex was not associated
with VACS Index score 1 year after ART initiation (β, +1.3,
95 % CI, −1.7 to 4.3) (Table 3). However, VACS Index
score at ART initiation, age, and poor ART adherence
were each significantly associated with score at 1 year
after ART initiation. In multivariable analysis, women’s
scores were 3.6 points higher (i.e. greater overall burden
of disease) than men (p=0.002). Thus, adjusted differ-
ences in VACS Index score were even greater than in
our unadjusted analyses. After further, adjustment for
ART adherence, women’s scores remained 3.2 points
higher than men (p=0.004).
DISCUSSION
HIV-infected women in the VA Healthcare system experi-
ence less improvement in overall burden of disease after
1 year of ART compared to HIV-infected men, a difference
Table 2. Characteristics of Combined Antiretroviral Therapy (ART)-Naïve HIV-Infected Women and Men in VA Care at ART Initiation
and 1 Year After ART Initiation
ART initiation One year after ART initiation
Women
(n=227) N (%)
Men
(n=8,073) N (%)
p Women
(n=227) N (%)
Men
(n=8073) N (%)
p
Age years < 50 190 (83.7) 4981 (61.7) < 0.001
50 to 64 37 (16.3) 2746 (34.0)
≥ 65 0 (0.0) 346 (4.3)
Race/ethnicity White 60 (26.4) 2794 (34.6) < 0.001
Black 157 (69.2) 4446 (55.1)
Hispanic 8 (3.5) 563 (7.0)
Other/Unknown 2 (0.9) 270 (3.3)
CD4 cells/mm3 ≥ 500 24 (10.6) 809 (10.0) 0.34 61 (26.9) 1837 (22.8) 0.60
350 to 499 38 (16.7) 1106 (13.7) 50 (22.0) 1640 (20.3)
200 to 349 70 (30.8) 2228 (27.6) 53 (23.3) 2101 (26.0)
100 to 199 39 (17.3) 1455 (18.0) 34 (15.0) 1413 (17.5)
50 to 99 15 (6.6) 796 (9.9) 12 (5.3) 494 (6.1)
< 50 41 (18.1) 1679 (20.8) 17 (7.5) 588 (7.3)
HIV RNA copies/mL < 500 0 (0) 0 (0) 0.24 130 (57.2) 4875 (60.4) 0.63
500 to 1×105 152 (67.0) 5097 (63.1) 78 (34.4) 2594 (32.1)
≥1×105 75 (33.0) 2976 (36.9) 19 (8.4) 604 (7.5)
Hemoglobin g/dL ≥ 14 26 (11.5) 3049 (37.8) < 0.001 38 (16.7) 4038 (50.0) < 0.001
12 to 13.9 93 (41.0) 3017 (37.4) 110 (48.5) 3006 (37.2)
10 to 11.9 78 (34.4) 1437 (17.8) 59 (26.0) 798 (9.9)
< 10 30 (13.2) 570 (7.1) 20 (8.8) 231 (2.9)
FIB-4 < 1.45 152 (67.0) 4192 (51.9) < 0.001 174 (76.7) 4945 (61.3) < 0.001
1.45 to 3.25 54 (23.8) 2942 (36.4) 41 (18.1) 2456 (30.4)
> 3.25 21 (9.3) 939 (11.6) 12 (5.3) 672 (8.3)
eGFR mL/min ≥ 60 217 (95.6) 7541 (93.4) 0.58 215 (94.7) 7391 (91.6) 0.35
45 to 59.9 6 (2.6) 281 (3.5) 8 (3.5) 380 (4.7)
30 to 44.9 2 (0.9) 102 (1.3) 2 (0.9) 127 (1.6)
< 30 2 (0.9) 149 (1.8) 2 (0.9) 175 (2.2)
Hepatitis C 69 (30.4) 2971 (36.8) 0.05
VACS Index 0 to 34 86 (37.9) 3159 (39.1) 0.44 139 (61.2) 5221 (64.7) 0.01
35 to 49 57 (25.1) 1677 (20.8) 55 (24.2) 1338 (16.6)
50 to 69 47 (20.7) 1760 (21.8) 18 (7.9) 965 (12.0)
70+ 37 (16.3) 1477 (18.3) 15 (6.6) 549 (6.8)
IQR interquartile range; FIB-4 Fibrosis Index; eGFR estimated Glomerular Filtration Rate
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only modestly explained by ART adherence. This study,
which utilized a large clinical cohort of HIV-infected
Veterans in VA-based HIV care, represents the first
comprehensive analysis of health outcomes for HIV-
infected women Veterans in VA care.
Our findings contribute to characterizing and understanding
health outcomes for HIV-infected women in VA care. By
using the VACS Index, a measure of overall burden of disease
that includes both HIVand non-HIV biomarkers, we were able
to go beyond what traditional measures (e.g. CD4 cell count)
tell us about morbidity to capture a more global assessment of
health among HIV-infected women Veterans, including their
response to treatment. This is particularly important, given the
increased contribution of non-AIDS defining disease to
morbidity and mortality in the ART era and the complex
interplay of HIV infection, ART and comorbid disease in an
aging HIV population. In validation studies of the VACS
Index, we also looked at whether hemoglobin level behaved
differently between women and men in its contribution to
VACS Index score and its association with mortality, and
found no evidence that it did.19 Further, VACS Index predicted
mortality rates matched observed rates as well for men as for
women.20 Results from prior studies of HIV-related sex
disparities using traditional HIV biomarkers have been mixed
with respect to whether or not sex differences exist in response
to ART;24–27 however, larger studies have found no sex
differences in ART response.28–31 How findings from these
studies would have differed if overall burden of disease were
assessed is unknown. Additionally, our study findings suggest
that differences in ART adherence only minimally contribute
to this disparity in ART response.
Our study has several limitations. First, to calculate
the VACS Index requires data on eight routine clinical
tests. However, we had complete data for over 80 % of
individuals in our study sample at the two clinical time
points. Second, since the study’s focus was on the VA
population, our results may not be generalizable to HIV-
infected persons who receive care outside the VA
healthcare system, as the VA HIV population is older
than the general HIV population. It is also affected by a
substantial burden of chronic comorbid disease,32,33
which has been increasingly ascribed to HIV-associated
chronic inflammation as well as ART-associated toxici-
ty.18,34–36 Additionally, HIV-infected women Veterans
Figure 1. Veterans Aging Cohort Study (VACS) index scores at combined antiretroviral therapy (ART) initiation and one year after ART
initiation. a VACS Index score, women; b VACS Index score, men.
Table 3. Association Between Patient Sex and Veterans Aging Cohort Study (VACS) Index Score at 1 Year After Combined Antiretroviral
Therapy (ART) Initiation
Unadjusted Model 1* Model 2†
β (95 % CI) P β (95 % CI) p β (95 % CI) P
Intercept 30.2 (29.8, 30.7) 28.6 (28.3, 29.0) 24.3 (23.8, 24.8)
Women vs. Men 1.3 (−1.7, 4.3) 0.39 3.6 (1.3, 5.9) 0.002 3.2 (1.0, 5.4) 0.004
VACS Index score at ART initiation, points 0.5 (0.5, 0.6) < 0.001 0.5 (0.5, 0.5) < 0.001 0.5 (0.5, 0.5) < 0.001
Age, 5-year increment 4.7 (4.4, 4.9) < 0.001 2.2 (2.0, 2.5) < 0.001 2.4 (2.2, 2.6) < 0.001
Adherence < 80 % 7.7 (6.7, 8.6) < 0.001 8.9 (8.2, 9.7) < 0.001
SE standard error
*Model 1 indicates adjusted for VACS Index score at ART initiation and age
†Model 2 indicates adjusted for VACS Index score at ART initiation, age, and poor ART adherence
Intercept represents men in unadjusted regression analysis; men, age 47 with VACS Index score of 42 at ART initiation in Model 1; and men, age 47,
with VACS Index score of 42 at ART initiation and adherence ≥ 80 % in Model 2
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may differ from HIV-infected women who are not
Veterans with respect to certain sociodemographic
characteristics and potential barriers to care, such as a
history of military sexual trauma.37 Third, by using data
in the medical record, we are limited in our ability to
qualitatively explore the experiences of HIV-infected
women Veterans in VA care and the various barriers
they may face that affect their interactions with VA
healthcare system. These experiences could be further
assessed in the future using the VACS prospective
cohort, in which patients complete annual question-
naires.33
We believe our findings have important implications
for the care of HIV-infected women Veterans and for
future research aimed at improving their health outcomes.
Further study is needed to elucidate modifiable factors
that may explain the observed sex disparity in ART
response, such as ART-associated toxicity. Prior research
suggests that women experience more and different types
of ART-related adverse events and toxicity compared with
men;38–40 this difference may affect health outcomes not
only due to increased discontinuation of ART, but to
direct toxic effects of ART. Also, the use of non-HIV
biomarkers in addition to traditional HIV biomarkers in
assessing overall burden of disease among HIV-infected
persons in care provides a more comprehensive evalua-
tion of health; potential differences between groups, such
as HIV-infected women and men in VA care, may not be
apparent when only traditional HIV biomarkers are
considered. This suggests that broader use of measures,
such as the VACS Index, in clinical care and research
would be useful. Future studies of this disparity in ART
response will need to explore the role of psychosocial
and structural factors that differentially impact women
Veterans, such as military sexual trauma, as well as
whether sex differences in ART response persist over
longer periods of follow-up.
In this study of HIV-infected Veterans in VA care,
women had less improvement in overall burden of
disease after 1 year on ART compared with men. As
HIV-infected women Veterans represent a vulnerable
group within a population already at high risk for poor
health outcomes, it is particularly important that the root
causes of this observed disparity be identified and
appropriately addressed.
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